Open access

Efficacy and safety of frail patients treated with ciltacabtagene autoleucel in the real world: A Center for International Blood and Marrow Transplant Research analysis

H. Mian M. Faisal Tie-Ning Chen R. Brazauskas Temitope Oloyede Nausheen Ahmed Aimaz Afrough Larry D. Anderson Rahul Banerjee Jesus G. Berdeja A. Bidikian Jakob Devos Binod Dhakal Ajoy L. Dias Danai Dima Yvonne A. Efebera Lohith Gowda Doris K. Hansen H. Hashmi H. Landau L. Lekakis A. Mirza R. Narra Krina K. Patel A. Rosko Mark A. Schroeder S. Sidana S. Usmani Marcelo C. Pasquini T. Nishihori O. Akhtar M. Mohan

Sep 2026 · Cancer · Vol 132 · 0 citations · 18 references

Medicine

Abstract

Ciltacabtagene autoleucel (cilta‐cel), an anti–B‐cell maturation antigen (BCMA) chimeric antigen receptor T‐cell (CAR‐T) therapy, is approved for relapsed/refractory multiple myeloma (RRMM).

DOI PubMed Semantic Scholar

Read PDF

Similar papers

Sep 2026

ENCERT: A Multisite Phase 1 Trial Using Everolimus in Combination With Nelarabine, Cyclophosphamide, and Etoposide in Relapsed T‐Cell Lymphoblastic Leukemia/Lymphoma

Relapsed and refractory (R/R) T‐cell acute lymphoblastic leukemia/lymphoma (T‐ALL/T‐LL) remains a therapeutic challenge. Allogeneic hematopoietic stem cell transplantation (HSCT) after achieving complete remission (CR) offers the only chance of cure, but effective modalities to achieve CR are limited. Activation of mTO...

Himalee S. Sabnis, M. Pauly, E. Schafer et al. · Pediatric Blood & Cancer · 0 citations

Open access Oct 2026

Outcomes of ibrutinib plus lenalidomide combination in patients with large Bcell lymphoma refractory to or relapsing after CAR-T-cell therapy and who failed or were ineligible for bispecific antibodies: a multicenter real-world REALI-T study.

Not available.

Carl J. Rudebeck, L. Fornecker, B. Guffroy et al. · Haematologica · 0 citations

Editorial Open access Sep 2026

Adaptations in pacritinib usage for myelofibrosis and thrombocytopenia since FDA approval

use of pacritinib in transplant-eligible MF patients. The study showed that pacri-tinib provided symptomatic benefit and that its use pre-transplant does not preclude alloHCT.

Valentina Ardila, S. Venugopal · Expert Review of Hematology · 0 citations

Clinical trial Open access Oct 2026

Eltrombopag during induction chemotherapy in older patients with newly diagnosed acute myeloid leukemia is safe and reduces platelet transfusion requirements: The EPAG‐2015 French Innovative Leukemia Organization phase 2 randomized trial

Elderly patients with acute myeloid leukemia (AML) treated with intensive chemotherapy are at risk of developing thrombopenia, which requires platelet transfusions. It would be interesting to provide them with thrombopoietin receptor agonists such as eltrombopag.

A. Pigneux, P. Dumas, Marc Bernard et al. · Cancer · 0 citations

Open access Sep 2026

Outcome after first relapse post‐immunochemotherapy in older adults with Philadelphia‐negative B‐cell acute lymphoblastic leukemia: A GRAALL study

Inotuzumab (InO)‐based frontline regimens have significantly improved the survival of older patients with Philadelphia‐negative (Ph–) B‐cell acute lymphoblastic leukemia (B‐ALL). Yet, outcome after relapse is not reported for this population.

Perrine Moyer, T. Leguay, M. Jullien et al. · Cancer · 0 citations

Open access Oct 2026

Real‐World Characteristics and Early Outcomes of Enfortumab Vedotin Plus Pembrolizumab in Advanced Urothelial Carcinoma

Enfortumab vedotin plus pembrolizumab (EV) plus pembrolizumab (EVP) has become a standard first‐line regimen for unresectable locally advanced or metastatic urothelial carcinoma.

T. Tsujino, K. Tamura, R. Taoka et al. · International journal of uro... · 0 citations